Mercer Global Advisors Inc. ADV lessened its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 1.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 145,759 shares of the company's stock after selling 2,411 shares during the period. Mercer Global Advisors Inc. ADV's holdings in Novartis were worth $14,184,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently modified their holdings of NVS. Virtu Financial LLC purchased a new stake in shares of Novartis in the 3rd quarter valued at approximately $427,000. World Investment Advisors LLC acquired a new stake in Novartis during the third quarter worth $3,873,000. Tidal Investments LLC raised its position in Novartis by 24.4% in the third quarter. Tidal Investments LLC now owns 5,680 shares of the company's stock valued at $653,000 after purchasing an additional 1,114 shares during the period. Synovus Financial Corp lifted its stake in shares of Novartis by 42.7% in the 3rd quarter. Synovus Financial Corp now owns 19,157 shares of the company's stock valued at $2,204,000 after purchasing an additional 5,728 shares during the last quarter. Finally, Versant Capital Management Inc grew its holdings in shares of Novartis by 782.0% during the 4th quarter. Versant Capital Management Inc now owns 785 shares of the company's stock worth $76,000 after purchasing an additional 696 shares during the period. Institutional investors and hedge funds own 13.12% of the company's stock.
Novartis Trading Up 2.7 %
Shares of NYSE:NVS opened at $114.35 on Friday. The company has a market cap of $241.56 billion, a PE ratio of 19.45, a P/E/G ratio of 1.70 and a beta of 0.56. The company's 50 day moving average is $110.13 and its two-hundred day moving average is $106.13. Novartis AG has a 52 week low of $96.06 and a 52 week high of $120.92. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48.
Novartis (NYSE:NVS - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, beating analysts' consensus estimates of $2.12 by $0.16. The business had revenue of $13.23 billion for the quarter, compared to the consensus estimate of $12.92 billion. Novartis had a return on equity of 37.24% and a net margin of 23.56%. The business's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.80 EPS. Equities analysts predict that Novartis AG will post 8.45 earnings per share for the current fiscal year.
Novartis Dividend Announcement
The business also recently announced a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were issued a $3.8695 dividend. The ex-dividend date was Wednesday, March 12th. Novartis's payout ratio is 44.05%.
Wall Street Analyst Weigh In
NVS has been the topic of a number of recent analyst reports. StockNews.com raised shares of Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 8th. Barclays reissued an "underweight" rating on shares of Novartis in a research report on Monday, February 3rd. UBS Group reaffirmed a "neutral" rating on shares of Novartis in a research note on Thursday, February 13th. Deutsche Bank Aktiengesellschaft upgraded Novartis from a "hold" rating to a "buy" rating in a report on Tuesday, February 4th. Finally, Morgan Stanley assumed coverage on shares of Novartis in a research note on Wednesday, February 12th. They set an "underweight" rating on the stock. Three analysts have rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $123.38.
View Our Latest Analysis on NVS
Novartis Company Profile
(
Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
